ProCE Banner Activity

CCO Think Tank on Emerging HER2-Targeted ADCs: Gastrointestinal Malignancies

Slideset

Slides from Zev A. Wainberg, MD, covering the recent developments in HER2 testing, clinical trial results for anti-HER2 antibody–drug conjugate (ADC) therapy, and current strategies for managing the safety profile of ADCs.

Released: March 20, 2024

Expiration: March 19, 2025

Share

Faculty

Zev A. Wainberg

Zev A. Wainberg, MD

Professor of Medicine and Surgery
Co-Director, GI Oncology
Director, Early Phase Clinical Research Program
Jonsson Comprehensive Cancer Center
UCLA School of Medicine
Los Angeles, California

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.